The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

Intercept Pharmaceuticals Inc

Nasdaq: ICPT
Last

(U.S.) $150.74

Today's change0.00 0.00%
Updated April 29 4:00 PM EDT. Delayed by at least 15 minutes.
 

Intercept Pharmaceuticals Inc

Nasdaq: ICPT
Last

(U.S.) $150.74

Today's change0.00 0.00%
Updated April 29 4:00 PM EDT. Delayed by at least 15 minutes.

Intercept Pharmaceuticals Inc closed at (U.S.)$150.74.

Shares have lost 4.44% over the last five days, but are unchanged over the last year to date. This security has underperformed the S&P 500 by 41.52% during the last year.

Key company metrics

  • Open(U.S.) $0.00
  • Previous close(U.S.) $150.74
  • High--
  • Low--
  • Bid / Ask(U.S.) $117.41 / (U.S.) $153.00
  • YTD % change+0.93%
  • Volume1,683
  • Average volume (10-day)418,115
  • Average volume (1-month)757,084
  • Average volume (3-month)723,725
  • 52-week range(U.S.) $89.76 to (U.S.) $314.88
  • Beta-2.43
  • Trailing P/ENegative, not meaningful
  • P/E 1 year forwardNegative, not meaningful
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) -$9.50
Updated April 29 4:00 PM EDT. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
-8,140.84%

Intercept Pharmaceuticals Inc has a net profit margin of -8,140.84%. Besides being negative, it is also below the industry average and implies that this company is not effective at turning revenues into bottom line profit.
Company Books

S&P TSX0.00%Sector:HealthcareIndustry:Biotechnology

Latest Company News

  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q4/2015Q3/2015Q2/2015Q1/2015
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedDec 31, 201512/31/2015Sep 30, 201509/30/2015Jun 30, 201506/30/2015Mar 31, 201503/31/2015
Revenue0001
Total other revenue--------
Total revenue0001
Gross profit--------
Total cost of revenue--------
Total operating expense89524941
Selling / general / administrative45252113
Research & development44272828
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)--------
Other operating expenses, total--------
Operating income-89-52-49-40
Interest income (expense), net non-operating--------
Gain (loss) on sale of assets--------
Other--------
Income before tax-88-51-48-39
Income after tax-88-51-48-39
Income tax, total--------
Net income-88-51-48-39
Total adjustments to net income--------
Net income before extra. items-88-51-48-39
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items-88-51-48-39
Inc. avail. to common incl. extra. items-88-51-48-39
Diluted net income-88-51-48-39
Dilution adjustment--------
Diluted weighted average shares24242422
Diluted EPS excluding extraordinary itemsvalue per share-3.62-2.10-1.99-1.78
Dividends per sharevalue per share0.000.000.000.00
Diluted normalized EPSvalue per share-3.62-2.10-1.99-1.78